Compare KN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | BEAM |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2013 | 2019 |
| Metric | KN | BEAM |
|---|---|---|
| Price | $33.64 | $31.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $28.00 | ★ $50.75 |
| AVG Volume (30 Days) | 885.7K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.94 | 82.31 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $593,200,000.00 | $24,000.00 |
| Revenue This Year | $9.40 | N/A |
| Revenue Next Year | $6.98 | $33.77 |
| P/E Ratio | $296.36 | ★ N/A |
| Revenue Growth | 7.17 | ★ 33.33 |
| 52 Week Low | $20.57 | $16.03 |
| 52 Week High | $42.93 | $38.26 |
| Indicator | KN | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 56.18 |
| Support Level | $23.97 | $28.03 |
| Resistance Level | $40.03 | $34.20 |
| Average True Range (ATR) | 1.36 | 1.21 |
| MACD | -0.63 | 0.47 |
| Stochastic Oscillator | 14.55 | 81.21 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.